Cocrystal Pharma (NASDAQ:COCP) Issues Quarterly Earnings Results

Cocrystal Pharma (NASDAQ:COCP) released its earnings results on Wednesday. The company reported ($0.19) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.03, Zacks reports.

Cocrystal Pharma Stock Performance

NASDAQ:COCP remained flat at $1.03 on Friday. 39,007 shares of the company’s stock traded hands, compared to its average volume of 177,798. The firm has a market capitalization of $10.58 million, a PE ratio of -0.83 and a beta of 2.24. The stock has a fifty day moving average price of $1.19 and a two-hundred day moving average price of $1.44. Cocrystal Pharma has a 12 month low of $1.00 and a 12 month high of $3.26.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cocrystal Pharma in a research note on Wednesday, October 8th. One investment analyst has rated the stock with a Buy rating and one has issued a Sell rating to the company. According to data from MarketBeat, Cocrystal Pharma presently has an average rating of “Hold” and an average price target of $6.00.

About Cocrystal Pharma

Cocrystal Pharma, Inc, a biotechnology company, focuses on the discovery and development of antiviral therapeutic treatments for serious and/or chronic viral diseases. It employs structure-based technologies to create antiviral drugs primarily to treat hepatitis C virus (HCV), influenza virus, coronavirus, norovirus, and respiratory virus infections.